OBJECTIVE -The objective of this study was to characterize treatment patterns among patients with diabetes presenting with non-ST-segment elevation (NSTE) acute coronary syndromes (ACSs). . In-hospital mortality rates were higher in insulin-treated diabetic (6.8%) and type 2 diabetic (5.4%) than in nondiabetic (4.4%) patients.
C ompared with nondiabetic patients, patients with diabetes have an increased incidence of acute coronary syndromes (ACSs) and worse cardiovascular outcomes, including an increased cardiovascular mortality rate (1) (2) (3) (4) . Recent prospective clinical trials supported these observations (5) (6) (7) (8) . However, these analyses are limited by several factors. Most data have been derived only from assessments of patients with ST-segment elevation myocardial infarction who are eligible for thrombolysis, representing only a minority of ACS patients. Other studies of broader cohorts are limited by their relatively small sample sizes, the small proportions of diabetic patients enrolled, or randomization processes with differing protocol-specified pharmacologic interventions (9) .
New findings underscore the importance of intensive treatment of diabetic patients. Several trials have consistently shown larger relative risk reductions for pharmacotherapies in the treatment of ACSs in diabetic patients versus nondiabetic patients. Because the absolute risk is larger in diabetic patients than in nondiabetic patients, the potential absolute benefit will also be larger in diabetic patients (10, 11) . This fact underscores the importance of using known evidencebased treatment for all ACS patients, especially diabetic patients. The most recent evidence-based guidelines for the treatment of non-ST-segment elevation (NSTE) ACS patients address and emphasize the need for early risk stratification of high-risk patients, early interventional management, and aggressive antiplatelet and antithrombotic therapy.
We sought to evaluate adherence to the American College of Cardiology (ACC)/American Heart Association (AHA) NSTE ACS treatment guidelines and differences in clinical outcomes among patients with and without diabetes included in the Can Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) national quality improvement initiative.
RESEARCH DESIGN AND METHODS -We evaluated 46,410 patients from 413 U.S. hospitals who presented with NSTE ACS (positive cardiac markers or ischemic ST-segment changes) and were included in the CRU-SADE national quality improvement initiative. CRUSADE is a prospective registry that was previously described in the literature; it includes patients who have chest pain or angina equivalent at rest for at least 10 min in duration within 24 h of presentation and either ischemic electrocardiographic changes (ST-segment depression Ͼ0.5 mm or transient STsegment elevation of 0.5-1.0 mm for Ͻ10 min in duration) or elevated levels of markers of myocardial necrosis (creatinine kinase-myocardial band or troponin) (12) . CRUSADE measures both the emergency department use of acute pharmacologic modalities (such as aspirin, heparin, ␤-blockers, and platelet inhibitors) and the in-hospital use of interventional therapies as recommended in the ACC/AHA 2002 guidelines as well as recommended discharge therapies. Patients are followed throughout their hospitalization to determine outcomes. Adherence to ACC/AHA guidelines was determined, taking into account both indications and contraindications for each individual patient. For example, utilization of ␤-blockers in the CRUSADE patient population was assessed only for those patients with indications for ␤-blockade.
After institutional review board approval was obtained at each site, the CRU-SADE registry analyzed patient records to determine compliance with 2002 ACC/ AHA guidelines for patients with NSTE ACS. Patients were stratified as nondiabetic, non-insulin-dependent diabetic (diabetes controlled by diet or oral medication, type 2 diabetes), or insulin-treated diabetic (diabetes being treated with insulin). Treatment recommendations from the ACC/AHA guidelines were reviewed, and utilization rates were compared among these groups. In addition, patients were followed throughout hospitalization for important clinical outcome measures including death, nonfatal myocardial infarction, and heart failure. RESULTS -Of the 46,410 patients presenting with NSTE ACS, 31,049 were nondiabetic, 9,773 were type 2 diabetic, and 5,588 were insulin-treated diabetic. Baseline characteristics are listed in Table  1 . Patients with type 2 diabetes and insulin-treated diabetes were older, were less commonly male, and more commonly had renal insufficiency and signs of congestive heart failure on presentation compared with nondiabetic patients.
Statistical analysis
Differences in usage of acute medication therapy and interventions are summarized in Tables 2 and 3 (Table 5) . ␤-Blocker, aspirin, lipidlowering agent, and clopidogrel therapies were equally likely to be used at discharge for all three groups (Table 5) . Whereas insulin-treated diabetic and type 2 diabetic patients were more likely to receive dietary counseling, they were less likely to receive smoking cessation counseling, although the difference was statistically significant only for insulin-treated diabetic patients.
After exclusion of patients with renal insufficiency (serum creatinine Ͼ2.0 mg/ dl, estimated creatinine clearance Ͻ30 ml/min, or need for dialysis), similar treatment disparities for certain medications and procedures were demonstrated. Acute (within 24 h) aspirin was used in 92.1% of nondiabetic patients, 91.2% of type 2 diabetic patients, and 89.1% of insulin-treated diabetic patients; heparin in 83.9, 83.1, and 79.8%; glycoprotein IIb/ IIIa inhibitors in 38.8, 34.2, and 26.9%; and early catheterization (within 48 h) in 52.0, 46.6, and 37.5%. Discharge aspirin and clopidogrel were used in 90.6 and 54.6% of nondiabetic patients, 89.7 and 51.4% of type 2 diabetic patients, and 87.8 and 48.0% of insulin-treated diabetic patients. The rates of death and of the composite end point of death or reinfarction were lowest in nondiabetic patients (3.7 and 6.3%) compared with type 2 diabetic patients (4.5 and 7.1%) and insulin-treated diabetic patients (5.8 and 8.7%) after patients with renal insufficiency were excluded.
CONCLUSIONS

Pathophysiologic alterations in diabetes
Both insulin-treated diabetes and type 2 diabetes are independent risk factors for coronary artery disease, stroke, and peripheral arterial disease (13, 14) . Diabetes induces alterations in the coagulation cascade with a shift toward a more prothrombotic state as well as an increase in platelet aggregation and adhesion (15, 16) . Autopsies have shown that diabetic patients have a more diffuse distribution of atherosclerotic lesions (17, 18) . Diabetic patients with established coronary artery disease undergoing cardiac catheterization for acute myocardial infarction, angioplasty, or coronary artery bypass grafting have significantly more severe proximal and distal coronary artery disease (5,19 -21) . In addition, postmortem and angioscopic evidence indicates an increase in ulcerated plaque morphology in diabetic patients (22, 23) .
McGuire et al. (24) demonstrated a significantly increased 30-day rate of reinfarction in diabetic patients without STsegment elevation on initial presentation compared with that in nondiabetic patients (9.0 vs. 5.3%, P Ͻ 0.0001). Effective use of antiplatelet and antithrombotic agents as recommended in the guidelines could be expected to address the underlying pathophysiologic process in diabetic patients.
CRUSADE results
Our study demonstrates that both type 2 diabetic and insulin-treated diabetic patients are at increased risk of death compared with nondiabetic patients. Despite this increased risk, insulin-treated diabetic patients are less likely to be treated with antiplatelet and antithrombotic agents (aspirin, heparin, glycoprotein IIb/ IIIa inhibitors, and ␤-blockers) and less likely to undergo cardiac catheterization and/or PCI, especially within 48 h. Even when patients with renal insufficiency were excluded, treatment disparities remained: specifically, decreased utilization of aspirin, heparin, and glycoprotein IIb/ IIIa inhibitors and early catheterization in insulin-treated diabetic patients compared with type 2 diabetic and nondiabetic patients. Similar trends were seen with discharge therapies such as aspirin and clopidogrel.
Our data are consistent with data from other clinical trials that evaluated acute myocardial infarction patients (but excluded high-risk unstable angina patients) before the use of newer agents such as low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors (25). Berger et al. 25 , who evaluated only patients Ͼ65 years of age, further demonstrated that diabetic patients, particularly those taking insulin, were less likely to receive aspirin or ␤-blockers and undergo coronary revascularization. Both type 2 diabetic and insulin-treated diabetic patients had higher 30-day and 1-year mortality than did nondiabetic patients, even after adjustment for demographic, clinical, hospital, and therapeutic differences. After adjustment for demographics, clinical and hospital characteristics, and treatment strategies, insulin-treated diabetic patients had the highest risk of mortality, followed by diabetic patients receiving oral hyperglycemic agents, followed by patients with diet-controlled diabetes. Mortality rates were significantly higher in these diabetic patients than in their nondiabetic counterparts. This led to a call for "preventative and therapeutic strategies targeted specifically at improving outcomes for diabetic patients." Our data suggest that in a very broad NSTE ACS high-risk population, this call has gone unheeded.
Future directions
The underutilization of various medical therapies (i.e., aspirin and ␤-blockers) and cardiac procedures (such as cardiac catheterization and coronary angioplasty) among diabetic patients raises clinical practice concerns because the efficacy of these therapies among diabetic patients has been validated in prior studies (26, 27) . Previous studies have suggested that the lower utilization of these more recent antiplatelet and antithrombotic therapies may be explained by a higher prevalence of comorbid disease and/or contraindications. However, we controlled for these variables (e.g., renal insufficiency) in our study, and significant differences in utilization of both medical and invasive acute treatments still persisted. Our study also represents a realworld sample of how diabetic patients are managed for NSTE ACS. Previous studies evaluating treatment of diabetic patients either focused on the ST-segment elevation myocardial infarction population alone or specifically excluded patients Ͻ65 years of age (25) . The relatively high prevalence of diabetes in our cohort (30%, consistent with the prevalence in an age-matched general population) compared with those observed in other clinical trials demonstrates that diabetic patients are underrepresented in clinical trial enrollment. This is a major strength of our study design. Thus, quality initiatives such as the CRUSADE registry highlight opportunities for improving care in the diabetic population.
Limitations
Our analysis has several limitations. First, we could not verify whether hospitals included consecutive patients with NSTE ACS, so the results may be subject to a sampling bias. Second, because this is an observational study, one cannot draw firm conclusions regarding cause and effect between less acute treatment and higher mortality. Third, we did not assess the relationship between the severity of the patient's diabetes and outcomes. Insulin-treated diabetic patients presumably had a more severe form of diabetes than did type 2 diabetic patients, but factors such as the duration of diabetes could not be assessed from the database, and HbA 1c was not measured. Lastly, the insulin-treated diabetic group represents a group of patients composed of insulindependent type 1 patients and type 2 patients currently being treated with insulin.
Summary
Diabetic patients have a higher risk of mortality than do nondiabetic patients, yet physicians adhere to the ACC/AHA NSTE ACS guidelines less often when treating diabetic patients, particularly insulin-treated diabetic patients. Increased use of guidelines-recommended therapies and early invasive management strategies in diabetic patients may improve the outcomes of these high-risk patients and should be evaluated in a clinical trial format.
